Tirzepatide + Retatrutide
Also known as: Tirz + Reta, Dual-agonist + triple-agonist blend
Pre-mixed metabolic blend combining tirzepatide, a GIP/GLP-1 dual receptor agonist, with retatrutide, an investigational GIP/GLP-1/glucagon triple receptor agonist, both acting on incretin pathways to reduce appetite and improve glucose handling and weight. Tirzepatide is FDA-approved as a finished prescription drug (Mounjaro/Zepbound) but combining it with retatrutide is not an approved use; retatrutide remains investigational in Phase 3 (Eli Lilly TRIUMPH, NDA anticipated late 2026). This specific blend is not an approved product and has no published controlled human efficacy or safety data — any rationale is inferred from the separate agents, and combination-specific human data is lacking.
Who's worth your money for Tirzepatide + Retatrutide
Every current seller, ranked by independent evidence — Merit Score, latest COA purity, and live $/mg (size-normalized). Prices refresh daily. Rankings are never paid.
No sellers for Tirzepatide + Retatrutide are indexed yet — we add vendors and their prices as we find them.
Watch Tirzepatide + Retatrutide
Get one email when the market actually moves — no newsletter, no noise.
About Tirzepatide + Retatrutide
CAS
—
Molecular formula
—
Typical dose range
No validated or approved blend protocol exists, and overlapping incretin agonism makes stacking redundant and higher-risk. Component references: tirzepatide 2.5–15 mg once weekly subcutaneous (approved titration); retatrutide ~2–12 mg once weekly subcutaneous in trials. Research use only.
Half-life
Component-dependent and not characterized for the mixture. Tirzepatide: ~5 days, supporting once-weekly dosing; retatrutide is likewise engineered for once-weekly dosing.
Common research uses
Safety notes
Not FDA-approved as a blend; only tirzepatide is approved as a standalone prescription product, while retatrutide is investigational and research/grey-market when sold loose. Combining two incretin agonists with overlapping GIP/GLP-1 activity offers no established benefit and can compound dose-dependent GI effects (nausea, vomiting, diarrhea) plus risks such as pancreatitis and gallbladder disease; retatrutide's glucagon agonism adds further effects under study. No combination-specific human safety data exists.
Reconstitution
Grey-market versions may be supplied lyophilized; reconstitute with bacteriostatic water and refrigerate. As an unapproved blend (including any compounded or research-sourced tirzepatide), dose accuracy, sterility and content are not assured.
COAs for Tirzepatide + Retatrutide
2 third-party tests across 1 vendor. Each card links to the full report.
15 citations indexed for Tirzepatide + Retatrutide
Study · 2026
Incretin-Based Dual and Triple Agonists in Overweight or Obese Individuals: A Systematic Review and Meta-Analysis
Incretin-based dual and triple agonists have emerged as effective options for obesity management, offering enhanced weight loss through multi-receptor agonism. However, data on their efficacy and safety remain limited.
Study · 2026
Beyond weight loss: Preserving muscle health in the incretin era
review · 2026
Evolution of incretin-based therapies: From GLP-1 monotherapy to dual and triple agonists: A new era in metabolic therapy
Incretin-based therapies have revolutionised the management of metabolic disorders, transitioning from DPP-4 inhibitors to advanced GLP-1 receptor agonists (GLP-1RAs) and next-generation dual and triple agonists.
Study · 2026
Trends in glucagon-like peptide-1 receptor agonist utilization and expenditure in Croatia
IntroductionGlucagon-like peptide-1 receptor agonists (GLP-1 RAs) have transformed the management of type 2 diabetes and obesity by improving glycemic control, promoting weight loss, and reducing cardiovascular risk.
review · 2026
Unregulated Peptide Use in the Age of Biohacking: Digital Promotion, Gray-Market Access, and Emerging Public Health Risks
Unregulated peptide use is emerging as a digitally mediated public health concern.
review · 2026
Anti-obesity medications and cognitive disorder risk: a discrepancy between RCTs and real-world evidence
Objectives To investigate the association between anti-obesity medication (AOM) use and the risk of cognitive disorder in individuals with overweight and obesity.
Research use only. Not for human consumption and not approved by the FDA.